When Deepinder Goyal wore a small sensor patch on his temple during a podcast appearance in early January, the Zomato founder wasn't just making a fashion statement. He was previewing Temple—his neurotech startup that just closed one of India's more unusual financing rounds: $54 million from a friends-and-family cohort that reads less like a cap table and more like a roster of the subcontinent's entrepreneurial elite.
The February 27, 2026 announcement laid bare the mechanics of what happens when a successful founder pivots. Goyal himself led the round with roughly $11.5 million (about INR 104 crore), securing a post-transaction stake around 28.59% in a company now valued at $190 million post-money. That's before Temple has shipped a single device.
A Cap Table That Looks Like a Founders' Reunion
What distinguishes this round isn't just the size—it's the density of operators willing to write checks. Steadview Capital anchored the institutional side with approximately INR 90.5 crore for a 5.28% stake. Peak XV Partners followed with around INR 54.30 crore (3.17%), while Dharana Capital and Info Edge Ventures each put in sizable amounts. Nikhil Kamath's NKSquared matched Info Edge's roughly INR 22.6 crore commitment, taking 1.32%.
But the angel roster is where things get interesting. Kunal Shah of CRED. Paytm's Vijay Shekhar Sharma. Both Kamath brothers from Zerodha. Mamaearth's Varun Alagh. The Cars24 team. Urban Company's Abhiraj Singh Bhal. Even content creator Raj Shamani—the same host whose podcast gave Temple its first real public visibility—joined in.
Several Zomato insiders participated too: CFO Akshant Goyal, along with executives Rahul Ganjoo and Aditya Mangla. It's the kind of syndicate that signals either strong founder credibility or a tight-knit bet among believers. Possibly both.
Here's the part that stands out, though. More than 30 Temple employees invested at the same valuation as institutional backers—no discount, no special terms. The company set aside a 10% ESOP pool valued at approximately INR 171 crore post-money, suggesting Goyal is betting that skin in the game builds better products.
The Science—and the Skepticism
Temple's central claim is audacious: a brain-monitoring wearable that tracks cerebral blood flow continuously via a sensor patch placed, naturally, on the temple. Goyal has positioned the device initially for elite athletes, promising measurements "no other wearable measures" at precision "that doesn't exist yet."
It's a big swing. Continuous CBF monitoring isn't standard fare in consumer tech—or even clinical settings outside specialized imaging. Some clinicians who reviewed early descriptions expressed caution about the feasibility and scientific rigor behind such claims. Which is fair. The device remains under development, with no firm launch date disclosed, though the company indicated in late February that a waitlist would open soon.
Temple emerged from Goyal's broader longevity research efforts through Continue Research, the venture he seeded with $25 million of personal capital last October. That project made waves in November by publishing the "Gravity Ageing Hypothesis"—a theory suggesting that lifelong gravity-driven reduction in cerebral blood flow contributes to ageing. The paper generated debate among scientists, with reactions ranging from intrigued to openly skeptical.
Whether the hypothesis holds up matters less, perhaps, than what it signals: Goyal isn't dabbling. He's going deep.
Hiring with a Catch
Alongside the funding news, Temple launched what can only be described as an aggressive—and eyebrow-raising—hiring push. The company is seeking specialists across analog and electronics design, embedded systems, sensor algorithms, deep learning, computational neuroscience, BCI engineering, neuroimaging machine learning, materials science, and various product roles.
The requirement that's generating headlines? Applicants must have body fat under 16% for men or 26% for women. Or commit to hitting those levels within three months.
It's a criterion that generated immediate controversy, for obvious reasons. Critics called it discriminatory; supporters framed it as consistent with Goyal's focus on performance optimization. Either way, it's unconventional—and likely intentional. Goyal has never been one to shy from controversy, and this seems designed to filter for a specific type of early employee: obsessive, optimization-minded, willing to buy into a founder's worldview wholesale.
Temple was incorporated back in April 2024 and now employs at least 30 people, if the employee investor count is accurate. For a startup still in stealth mode, that's a sizable team—one that suggests product development is further along than the public narrative lets on.
What Comes Next
The $54 million round gives Temple runway to build, test, and—eventually—launch. But questions linger. Can the startup deliver on the scientific promises? Will athletes, or anyone else, actually want continuous brain monitoring? And what happens if early results don't match the hype?
Goyal's track record offers some reassurance. Zomato went from food delivery startup to public company, navigating regulatory battles and market skepticism along the way. But neurotech is different—harder science, tighter regulations, and a consumer base that tends to be wary of unproven health claims.
For now, the investor base seems willing to wait and see. With over 80 angels and a handful of India's sharpest institutional backers on board, Temple has the capital—and perhaps more importantly, the network—to take its shot. Whether that translates to a device people actually wear remains the open question.
